Segment Information

12 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Segment Information

(19) Segment Information

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

Human Health - includes finished dosage form generic drugs and nutraceutical products.

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated Totals
2017
Net sales	$	315,395	$	157,445	$	165,478	$	-		$	638,318
Gross profit		78,109		25,474		37,209		-			140,792
Income before income taxes		15,434		9,322		18,829		(26,224	)		17,361
2016
Net sales	$	228,035	$	161,011	$	169,478	$	-		$	558,524
Gross profit		77,880		28,752		36,153		-			142,785
Income before income taxes		36,362		11,856		17,799		(12,163	)		53,854
2015
Net sales	$	225,263	$	149,296	$	172,392	$	-		$	546,951
Gross profit		75,749		26,683		33,002		-			135,434
Income before income taxes		35,152		8,697		14,289		(4,273	)		53,865

Net sales and gross profit by source country for the years ended June 30, 2017, 2016 and 2015 were as follows:

	Net Sales						Gross Profit
	2017		2016		2015		2017		2016		2015
United States	$	483,678	$	400,883	$	407,101	$	116,792	$	117,180	$	111,734
Germany		79,105		76,666		69,889		13,609		15,154		14,660
Netherlands		9,949		16,217		14,656		1,231		1,598		1,325
France		35,796		30,177		27,976		4,651		4,043		3,634
Asia-Pacific		29,790		34,581		27,329		4,509		4,810		4,081
Total	$	638,318	$	558,524	$	546,951	$	140,792	$	142,785	$	135,434

Sales generated from the United States to foreign countries amounted to $21,750, $23,810 and $38,295 for the fiscal years ended June 30, 2017, 2016 and 2015, respectively.

Long-lived assets by geographic region as of June 30, 2017 and June 30, 2016 were as follows:

	Long-lived assets
	2017		2016
United States	$	528,359	$	152,701
Europe		2,538		2,504
Asia-Pacific		1,582		1,781
Total	$	532,479	$	156,986